Company Overview

Nabriva Therapeutics plc is an anti-infective biopharmaceutical company focused on the development and commercialization of antibiotics for serious bacterial infections. The company historically operated in the biotechnology and specialty pharmaceutical sectors, with an emphasis on addressing antimicrobial resistance and hospital- and community-acquired infections. Its primary asset has been XENLETA (lefamulin), a pleuromutilin antibiotic approved in the United States for the treatment of community-acquired bacterial pneumonia (CABP). The company also advanced CONTEPO (fosfomycin for injection) for complicated urinary tract infections and other serious bacterial infections, although regulatory and development challenges affected commercialization progress.

Nabriva was founded in Austria and later established operations in Ireland and the United States, evolving from a research-oriented anti-infectives developer into a commercial-stage biotechnology company. The company pursued differentiation through its focus on novel antibiotic mechanisms and treatments targeting drug-resistant pathogens. Public filings and market disclosures indicate that Nabriva faced significant financial constraints in recent years, including restructuring activities, workforce reductions, and strategic reviews. Trading activity for the company’s shares transitioned from Nasdaq to over-the-counter markets under the ticker NBRVF after delisting proceedings.

Business Operations

Nabriva’s operations historically centered on a single primary business segment focused on anti-infective therapeutics. Revenue generation was primarily tied to product commercialization efforts for XENLETA, licensing arrangements, milestone payments, and financing activities rather than diversified recurring commercial operations. The company’s commercial activities were concentrated largely in the United States, where it established sales and medical affairs infrastructure for hospital and infectious disease markets. Research and development operations included clinical trials, regulatory submissions, pharmacovigilance, and manufacturing oversight through third-party contract organizations.

The company relied extensively on external partnerships for manufacturing, distribution, and development support. Nabriva maintained relationships with contract development and manufacturing organizations rather than owning large-scale production facilities. Its intellectual property portfolio included patents related to pleuromutilin antibiotics and anti-infective formulations. Public disclosures also referenced collaboration and licensing arrangements connected to regional commercialization rights and development activities. Data regarding ongoing active commercial partnerships after restructuring actions is inconclusive based on available public sources.

Strategic Position & Investments

Nabriva’s strategic direction focused on building a specialized anti-infectives platform addressing unmet medical needs associated with bacterial resistance. The company invested heavily in the clinical development and commercialization of XENLETA, positioning the product as a differentiated antibiotic with both oral and intravenous formulations. It also pursued regulatory advancement of CONTEPO, viewing it as a potential treatment option for multidrug-resistant infections. Strategic efforts included securing regulatory approvals, expanding physician awareness, and pursuing reimbursement access in the hospital and outpatient settings.

The company financed operations through equity offerings, debt arrangements, licensing transactions, and strategic capital raises. Public filings indicate that Nabriva evaluated strategic alternatives amid liquidity pressures, including restructuring initiatives and operational streamlining. Unlike larger pharmaceutical companies, Nabriva did not maintain a broad portfolio of subsidiaries or diversified therapeutic holdings. Its strategic value was primarily concentrated in its anti-infective intellectual property and approved antibiotic assets. Information regarding substantial recent acquisitions or large-scale investment programs is limited in publicly available filings.

Geographic Footprint

Nabriva Therapeutics plc maintained a multinational corporate structure with roots in Austria, legal incorporation in Ireland, and substantial operational activity in the United States. Its headquarters functions were associated with Dublin, while commercial and operational activities were conducted primarily through U.S.-based offices focused on regulatory, clinical, and commercialization efforts. The company targeted the U.S. antibiotic market as its principal commercial opportunity because of market size, reimbursement potential, and infectious disease treatment demand.

The company also pursued international regulatory and licensing opportunities across Europe and other regions through partnerships and development activities. Clinical development programs involved multinational trial sites and regulatory interactions with agencies including the U.S. Food and Drug Administration and European authorities. Despite its international structure, publicly available information indicates that the majority of revenue opportunities and operational focus remained concentrated in North America.

Leadership & Governance

Nabriva was founded by executives and scientists focused on anti-infective drug development, with governance structured around a public biotechnology company model overseen by a board of directors and executive leadership team. Over time, leadership changes reflected the company’s transition from clinical-stage development to commercialization and later restructuring efforts. Strategic priorities emphasized advancing novel antibiotics, securing regulatory approvals, and preserving operational liquidity amid competitive and financial pressures.

Key executives and leadership figures identified in public filings and company disclosures have included:

• Michael P. Wetzler – Chief Executive Officer
• Ted Schroeder – Former Chief Executive Officer
• Alison H. B. Fleming – Chief Financial Officer
• Robert J. Gaynor, M.D. – Former Chief Medical Officer
• Jennifer Good – Former Chief Executive Officer and board leadership roles associated with restructuring activities

Public governance disclosures referenced oversight through board committees responsible for audit, compensation, and corporate governance functions consistent with publicly traded biotechnology companies. Certain executive and board roles changed during restructuring periods, and some leadership information may vary across reporting periods due to management transitions and corporate restructuring activities.